



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/635,820	08/07/2003	Philip Chidi Njemanze		7656

23534 7590 10/03/2005

PHILIP CHIDI NJEMANZE
NO 1 URATTA/MCC ROAD
P O BOX 302
OWERI, POB302
NIGERIA

EXAMINER

JONES, DAMERON LEVEST

ART UNIT PAPER NUMBER

1618

DATE MAILED: 10/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10/635,820 8/7/03 Njemanze

EXAMINER

D. Jones

ART UNIT	PAPER
----------	-------

1618


09292005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Please see the attached notice regarding the response submitted on 7/26/05.


D. L. Jones
Primary Examiner
Art Unit: 1618
9/29/05

NON-RESPONSIVE AMENDMENT

The reply filed on 7/26/05 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s). It is noted that in response to the restriction requirement mailed 6/29/05, Applicant has elected Group II, claims 9-13, drawn to a method and system for controlling infectious diseases as set forth in independent claim 9. However, Applicant has elected the hydrophobic/hydrophilic ingredients of claims 10-13; the targeted tissue cells of claims 9 and 12, the infectious diseases of claims 10-13; the tissue specific peptide, natural protein channels, and tissue specific membrane proteins as set forth in claim 12; the specific drugs of claims 10, 11, and 13. Thus, the amendment is non-responsive because Applicant needs to elect a single (one component) from each of the subgroups (a single hydrophobic and/or hydrophilic ingredient; a single targeted tissue cell; a single infectious disease; etc.) above, not each species disclosed in the claim.


See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


A.D. L. Jones
Primary Examiner
Art Unit 1618

September 29, 2005